カテゴリ： Allied Market Research, 世界, 医療/バイオ

耳鼻咽喉科（ENT）疾患治療のグローバル市場（2020～2030）：抗生物質、抗炎症薬、その他

■ 英語タイトル：ENT Disorder Treatment Market By Drug Type (Antibiotics Drugs, Anti Inflammatory Drugs, Others), By Organ (Throat, Ear, Nose), By End User (Hospital and clinics, Homecare Settings, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
	■ 発行会社/調査会社：Allied Market Research ■ 商品コード：ALD23JN092 ■ 発行日：2022年9月 ■ 調査対象地域：グローバル ■ 産業分野：生命科学 ■ ページ数：334 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール（受注後24時間以内）

■ 販売価格オプション（消費税別）

Online Only（1名閲覧、印刷不可）	USD3,570 ⇒換算￥542,640	見積依頼/購入/質問フォーム
Single User（1名閲覧）	USD5,730 ⇒換算￥870,960	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）	USD9,600 ⇒換算￥1,459,200	見積依頼/購入/質問フォーム

※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[耳鼻咽喉科（ENT）疾患治療のグローバル市場（2020～2030）：抗生物質、抗炎症薬、その他]についてメールでお問い合わせはこちら

*** レポート概要（サマリー）***

Allied Market Research社の本レポートでは、2021年に2,370.59百万ドルであった世界の耳鼻咽喉科（ENT）疾患治療市場規模が2031年には4,496.58百万ドルに達し、2022年から2031年にかけて年平均6.5％成長すると予測しています。Allied Market Research社の本レポートでは、世界の耳鼻咽喉科（ENT）疾患治療市場について幅広く調査し、イントロダクション、エグゼクティブサマリー、市場概要、薬剤別分析（抗生物質、抗炎症薬、その他）、臓器別分析（喉、耳、鼻）、エンドユーザー別分析（病院＆診療所、在宅医療、その他）、地域別分析（北米、ヨーロッパ、アジア太平洋、中南米/中東・アフリカ）、企業状況、企業情報など、以下の内容を掲載しています。さらに、Pfizer Inc、Teva Pharmaceuticals、Novartis、Glaxosmithkline plc、Bayer Ag、Sanofi、Amneal Pharmceuticals Ltd、Astrazenca Plc、Mylan N.V.、Akira Healthcare、Aurbindo pharmaなどの企業情報が含まれています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の耳鼻咽喉科（ENT）疾患治療市場規模：薬剤別分析
- 抗生物質の市場規模
- 抗炎症薬の市場規模
- その他薬剤の市場規模
・世界の耳鼻咽喉科（ENT）疾患治療市場規模：臓器別分析
- 喉における市場規模
- 耳における市場規模
- 鼻における市場規模
・世界の耳鼻咽喉科（ENT）疾患治療市場規模：エンドユーザー別分析
- 病院＆診療所における市場規模
- 在宅医療における市場規模
- その他エンドユーザーにおける市場規模
・世界の耳鼻咽喉科（ENT）疾患治療市場規模：地域別分析
- 北米の耳鼻咽喉科（ENT）疾患治療市場規模
- ヨーロッパの耳鼻咽喉科（ENT）疾患治療市場規模
- アジア太平洋の耳鼻咽喉科（ENT）疾患治療市場規模
- 中南米/中東・アフリカの耳鼻咽喉科（ENT）疾患治療市場規模
・企業状況
・企業情報

世界の耳鼻咽喉科（ENT）疾患治療市場は、2021年には23億7,059万ドル、2031年には44億9,658万ドルに達すると予測され、2022年から2031年までの年平均成長率は6.5%となる見込みです。
耳、鼻、喉は身体の重要な部分です。耳は、音を聞いたり、体全体のバランスを保ったりする感覚器官です。一方、喉は空気、水、食べ物の通り道です。様々な疾患によってこれらの器官のいずれかが機能不全に陥ると、生活の質に直接影響を及ぼします。一般的な耳鼻咽喉科疾患には、耳感染症、副鼻腔感染症、扁桃炎、音響神経腫、メニエール病などがあります。耳鼻咽喉科疾患の治療には、鼻の充血除去スプレー、経口および外用の抗ヒスタミン薬、鼻用ステロイド、鼻用生理食塩水洗浄など、幅広い種類の薬剤が使用されます。さらに、耳の感染症を治療するために、さまざまな抗生物質が利用可能です。

市場の成長を促進する主な要因は、環境条件の急速な変化、大気汚染や騒音公害のレベルの増加、高齢者人口の増加です。高齢者人口は免疫力が低いため感染しやすく、これが市場の成長をさらに促進します。例えば、インドの人口予測に関する技術グループが発表した報告書によると、インドでは2021年に約1億3,800万人が60歳以上になり、2031年にはさらに増加すると予想されています。このように、高齢者人口の増加は、点耳薬や、鼻・耳・喉の感染症を治療する抗生物質の需要を急増させ、市場の成長を牽引しています。

また、副鼻腔炎や慢性鼻炎の世界的な有病率の上昇が市場の成長をさらに促進します。さらに、発展途上国における医療費の増加や政府のイニシアチブの増加が、市場の成長をさらに後押しする主な要因となっています。
しかし、医療機器や副鼻腔炎・扁桃腺炎の手術にかかる費用が高いことが市場成長の妨げとなっています。逆に、発展途上国における新興医療市場は、予測期間中の市場成長に有利な機会を提供すると期待されています。

耳鼻咽喉科（ENT）疾患治療市場は、薬剤タイプ、臓器、エンドユーザー、地域によって区分されます。
薬剤タイプ別では、抗生物質、抗炎症剤、その他に分類されます。
臓器別では、耳、鼻、喉に分類されます。
エンドユーザー別では、病院＆診療所、在宅医療、その他に分類されます。
地域別では、北米、欧州、アジア太平洋、LAMEAに市場を分けて分析しています。

北米は、2021年の耳鼻咽喉科（ENT）疾患治療市場シェアの大半を占め、同地域の医療費の増加、同国における主要プレイヤーの存在、および彼らが製品開発のために採用する戦略により、予測期間中も支配的であると予測されています。
アジア太平洋地域は、環境汚染の増加、高齢者人口の増加、鼻感染症、感染症およびアレルギー疾患の有病率の増加により、2021年の市場貢献第2位であり、予測期間中に最も速いCAGRを記録すると予想されています。

耳鼻咽喉科（ENT）疾患治療市場で事業を展開する主要企業は、Sanofi、Novartis、GSK、Pfizer、Vitaris、Sun Pharma、AstraZeneca、Cipla、AurbindoPharma、Teva Pharmaceuticals、Bayer AG、Amneal Pharmaceuticals Ltd、M.M Pharma、Lyra Therapeutics、Lannet Company Inc.などです。

〈ステークホルダーにとっての主なメリット〉
・本レポートは、2021年から2031年までの耳鼻咽喉科（ENT）疾患治療市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、耳鼻咽喉科（ENT）疾患治療の市場機会を特定します。
・主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるようにします。
・耳鼻咽喉科（ENT）疾患治療市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・地域および世界の耳鼻咽喉科（ENT）疾患治療市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
薬剤タイプ別
抗生物質薬
抗炎症薬
その他

臓器別
喉
扁桃炎
咽頭炎
扁桃咽頭炎
その他
耳
中耳炎
外耳炎
メニエール病
耳真菌症
その他
鼻
副鼻腔炎
鼻炎
鼻ポリープ
その他

エンドユーザー別
その他
病院＆診療所
在宅医療

地域別
・北米
米国
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
オーストラリア
インド
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
Pfizer Inc
Teva Pharmaceuticals
Novartis
Glaxosmithkline plc
Bayer Ag
Sanofi
Amneal Pharmceuticals Ltd
Astrazenca Plc
Mylan N.V.
Akira Healthcare
Aurbindo pharma

*** レポート目次（コンテンツ）***

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: ENT DISORDER TREATMENT MARKET, BY DRUG TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Antibiotics Drugs
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Anti Inflammatory Drugs
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Others
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
CHAPTER 5: ENT DISORDER TREATMENT MARKET, BY ORGAN
5.1 Overview
5.1.1 Market size and forecast
5.2 Throat
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.2.4 Throat ENT Disorder Treatment Market by Disease Type
5.2.4.1 Tonsillitis Market size and forecast, by region
5.2.4.2 Pharyngitis Market size and forecast, by region
5.2.4.3 Tonsillopharyngitis Market size and forecast, by region
5.2.4.4 Others Market size and forecast, by region
5.3 Ear
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.3.4 Ear ENT Disorder Treatment Market by Disease Type
5.3.4.1 Otitis Media Market size and forecast, by region
5.3.4.2 Otitis Externa Market size and forecast, by region
5.3.4.3 Meniere’s Disease Market size and forecast, by region
5.3.4.4 Otomycosis Market size and forecast, by region
5.3.4.5 Others Market size and forecast, by region
5.4 Nose
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.4.4 Nose ENT Disorder Treatment Market by Disease Type
5.4.4.1 Sinusitis Market size and forecast, by region
5.4.4.2 Rhinitis Market size and forecast, by region
5.4.4.3 Nasal Polyps Market size and forecast, by region
5.4.4.4 Others Market size and forecast, by region
CHAPTER 6: ENT DISORDER TREATMENT MARKET, BY END USER
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital and clinics
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Homecare Settings
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Others
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: ENT DISORDER TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Drug Type
7.2.3 North America Market size and forecast, by Organ
7.2.3.1 North America Throat ENT Disorder Treatment Market by Disease Type
7.2.3.2 North America Ear ENT Disorder Treatment Market by Disease Type
7.2.3.3 North America Nose ENT Disorder Treatment Market by Disease Type
7.2.4 North America Market size and forecast, by End User
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Drug Type
7.2.5.1.2 Market size and forecast, by Organ
7.2.5.1.3 Market size and forecast, by End User
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Drug Type
7.2.5.2.2 Market size and forecast, by Organ
7.2.5.2.3 Market size and forecast, by End User
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Drug Type
7.2.5.3.2 Market size and forecast, by Organ
7.2.5.3.3 Market size and forecast, by End User
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Drug Type
7.3.3 Europe Market size and forecast, by Organ
7.3.3.1 Europe Throat ENT Disorder Treatment Market by Disease Type
7.3.3.2 Europe Ear ENT Disorder Treatment Market by Disease Type
7.3.3.3 Europe Nose ENT Disorder Treatment Market by Disease Type
7.3.4 Europe Market size and forecast, by End User
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Drug Type
7.3.5.1.2 Market size and forecast, by Organ
7.3.5.1.3 Market size and forecast, by End User
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Drug Type
7.3.5.2.2 Market size and forecast, by Organ
7.3.5.2.3 Market size and forecast, by End User
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Drug Type
7.3.5.3.2 Market size and forecast, by Organ
7.3.5.3.3 Market size and forecast, by End User
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Drug Type
7.3.5.4.2 Market size and forecast, by Organ
7.3.5.4.3 Market size and forecast, by End User
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Drug Type
7.3.5.5.2 Market size and forecast, by Organ
7.3.5.5.3 Market size and forecast, by End User
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Drug Type
7.3.5.6.2 Market size and forecast, by Organ
7.3.5.6.3 Market size and forecast, by End User
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Drug Type
7.4.3 Asia-Pacific Market size and forecast, by Organ
7.4.3.1 Asia-Pacific Throat ENT Disorder Treatment Market by Disease Type
7.4.3.2 Asia-Pacific Ear ENT Disorder Treatment Market by Disease Type
7.4.3.3 Asia-Pacific Nose ENT Disorder Treatment Market by Disease Type
7.4.4 Asia-Pacific Market size and forecast, by End User
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Drug Type
7.4.5.1.2 Market size and forecast, by Organ
7.4.5.1.3 Market size and forecast, by End User
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Drug Type
7.4.5.2.2 Market size and forecast, by Organ
7.4.5.2.3 Market size and forecast, by End User
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Drug Type
7.4.5.3.2 Market size and forecast, by Organ
7.4.5.3.3 Market size and forecast, by End User
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Drug Type
7.4.5.4.2 Market size and forecast, by Organ
7.4.5.4.3 Market size and forecast, by End User
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Drug Type
7.4.5.5.2 Market size and forecast, by Organ
7.4.5.5.3 Market size and forecast, by End User
7.4.5.6 Rest Of Asia- Pacific
7.4.5.6.1 Market size and forecast, by Drug Type
7.4.5.6.2 Market size and forecast, by Organ
7.4.5.6.3 Market size and forecast, by End User
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Drug Type
7.5.3 LAMEA Market size and forecast, by Organ
7.5.3.1 LAMEA Throat ENT Disorder Treatment Market by Disease Type
7.5.3.2 LAMEA Ear ENT Disorder Treatment Market by Disease Type
7.5.3.3 LAMEA Nose ENT Disorder Treatment Market by Disease Type
7.5.4 LAMEA Market size and forecast, by End User
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Drug Type
7.5.5.1.2 Market size and forecast, by Organ
7.5.5.1.3 Market size and forecast, by End User
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Drug Type
7.5.5.2.2 Market size and forecast, by Organ
7.5.5.2.3 Market size and forecast, by End User
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Drug Type
7.5.5.3.2 Market size and forecast, by Organ
7.5.5.3.3 Market size and forecast, by End User
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Drug Type
7.5.5.4.2 Market size and forecast, by Organ
7.5.5.4.3 Market size and forecast, by End User
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Pfizer Inc
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Teva Pharmaceuticals
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Novartis
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Glaxosmithkline plc
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Bayer Ag
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Sanofi
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Amneal Pharmceuticals Ltd
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Astrazenca Plc
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Mylan N.V.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Akira Healthcare
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
9.11 Aurbindo pharma
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Operating business segments
9.11.4 Product portfolio
9.11.5 Business performance
9.11.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 2. ENT DISORDER TREATMENT MARKET SIZE, FOR ANTIBIOTICS DRUGS, BY REGION, 2021-2031 ($MILLION)
TABLE 3. ENT DISORDER TREATMENT MARKET FOR ANTIBIOTICS DRUGS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. ENT DISORDER TREATMENT MARKET SIZE, FOR ANTI INFLAMMATORY DRUGS, BY REGION, 2021-2031 ($MILLION)
TABLE 5. ENT DISORDER TREATMENT MARKET FOR ANTI INFLAMMATORY DRUGS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. ENT DISORDER TREATMENT MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 7. ENT DISORDER TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 8. GLOBAL ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
TABLE 9. ENT DISORDER TREATMENT MARKET SIZE, FOR THROAT, BY REGION, 2021-2031 ($MILLION)
TABLE 10. ENT DISORDER TREATMENT MARKET FOR THROAT, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 11. GLOBAL THROAT ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 12. ENT DISORDER TREATMENT MARKET, FOR TONSILLITIS, BY REGION, 2021-2031 ($MILLION)
TABLE 13. ENT DISORDER TREATMENT MARKET, FOR PHARYNGITIS, BY REGION, 2021-2031 ($MILLION)
TABLE 14. ENT DISORDER TREATMENT MARKET, FOR TONSILLOPHARYNGITIS, BY REGION, 2021-2031 ($MILLION)
TABLE 15. ENT DISORDER TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 16. ENT DISORDER TREATMENT MARKET SIZE, FOR EAR, BY REGION, 2021-2031 ($MILLION)
TABLE 17. ENT DISORDER TREATMENT MARKET FOR EAR, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 18. GLOBAL EAR ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 19. ENT DISORDER TREATMENT MARKET, FOR OTITIS MEDIA, BY REGION, 2021-2031 ($MILLION)
TABLE 20. ENT DISORDER TREATMENT MARKET, FOR OTITIS EXTERNA, BY REGION, 2021-2031 ($MILLION)
TABLE 21. ENT DISORDER TREATMENT MARKET, FOR MENIERE’S DISEASE, BY REGION, 2021-2031 ($MILLION)
TABLE 22. ENT DISORDER TREATMENT MARKET, FOR OTOMYCOSIS, BY REGION, 2021-2031 ($MILLION)
TABLE 23. ENT DISORDER TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 24. ENT DISORDER TREATMENT MARKET SIZE, FOR NOSE, BY REGION, 2021-2031 ($MILLION)
TABLE 25. ENT DISORDER TREATMENT MARKET FOR NOSE, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 26. GLOBAL NOSE ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 27. ENT DISORDER TREATMENT MARKET, FOR SINUSITIS, BY REGION, 2021-2031 ($MILLION)
TABLE 28. ENT DISORDER TREATMENT MARKET, FOR RHINITIS, BY REGION, 2021-2031 ($MILLION)
TABLE 29. ENT DISORDER TREATMENT MARKET, FOR NASAL POLYPS, BY REGION, 2021-2031 ($MILLION)
TABLE 30. ENT DISORDER TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 31. GLOBAL ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 32. ENT DISORDER TREATMENT MARKET SIZE, FOR HOSPITAL AND CLINICS, BY REGION, 2021-2031 ($MILLION)
TABLE 33. ENT DISORDER TREATMENT MARKET FOR HOSPITAL AND CLINICS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 34. ENT DISORDER TREATMENT MARKET SIZE, FOR HOMECARE SETTINGS, BY REGION, 2021-2031 ($MILLION)
TABLE 35. ENT DISORDER TREATMENT MARKET FOR HOMECARE SETTINGS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 36. ENT DISORDER TREATMENT MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 37. ENT DISORDER TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 38. ENT DISORDER TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 39. NORTH AMERICA ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 40. NORTH AMERICA ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
TABLE 41. NORTH AMERICA THROAT ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 42. NORTH AMERICA EAR ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 43. NORTH AMERICA NOSE ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 44. NORTH AMERICA ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 45. NORTH AMERICA ENT DISORDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 46. U.S. ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 47. U.S. ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
TABLE 48. U.S. ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 49. CANADA ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 50. CANADA ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
TABLE 51. CANADA ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 52. MEXICO ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 53. MEXICO ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
TABLE 54. MEXICO ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 55. EUROPE ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 56. EUROPE ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
TABLE 57. EUROPE THROAT ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 58. EUROPE EAR ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 59. EUROPE NOSE ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 60. EUROPE ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 61. EUROPE ENT DISORDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 62. GERMANY ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 63. GERMANY ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
TABLE 64. GERMANY ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 65. FRANCE ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 66. FRANCE ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
TABLE 67. FRANCE ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 68. UK ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 69. UK ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
TABLE 70. UK ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 71. ITALY ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 72. ITALY ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
TABLE 73. ITALY ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 74. SPAIN ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 75. SPAIN ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
TABLE 76. SPAIN ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 77. REST OF EUROPE ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 78. REST OF EUROPE ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
TABLE 79. REST OF EUROPE ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 80. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 81. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
TABLE 82. ASIA-PACIFIC THROAT ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 83. ASIA-PACIFIC EAR ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 84. ASIA-PACIFIC NOSE ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 85. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 86. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 87. JAPAN ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 88. JAPAN ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
TABLE 89. JAPAN ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 90. CHINA ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 91. CHINA ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
TABLE 92. CHINA ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 93. AUSTRALIA ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 94. AUSTRALIA ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
TABLE 95. AUSTRALIA ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 96. INDIA ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 97. INDIA ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
TABLE 98. INDIA ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 99. SOUTH KOREA ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 100. SOUTH KOREA ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
TABLE 101. SOUTH KOREA ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 102. REST OF ASIA- PACIFIC ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 103. REST OF ASIA- PACIFIC ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
TABLE 104. REST OF ASIA- PACIFIC ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 105. LAMEA ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 106. LAMEA ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
TABLE 107. LAMEA THROAT ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 108. LAMEA EAR ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 109. LAMEA NOSE ENT DISORDER TREATMENT MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 110. LAMEA ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 111. LAMEA ENT DISORDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 112. BRAZIL ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 113. BRAZIL ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
TABLE 114. BRAZIL ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 115. SAUDI ARABIA ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 116. SAUDI ARABIA ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
TABLE 117. SAUDI ARABIA ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 118. SOUTH AFRICA ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 119. SOUTH AFRICA ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
TABLE 120. SOUTH AFRICA ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 121. REST OF LAMEA ENT DISORDER TREATMENT MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 122. REST OF LAMEA ENT DISORDER TREATMENT MARKET, BY ORGAN, 2021-2031 ($MILLION)
TABLE 123. REST OF LAMEA ENT DISORDER TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 124.PFIZER INC: COMPANY SNAPSHOT
TABLE 125.PFIZER INC: OPERATING SEGMENTS
TABLE 126.PFIZER INC: PRODUCT PORTFOLIO
TABLE 127.PFIZER INC: NET SALES,
TABLE 128.PFIZER INC: KEY STRATERGIES
TABLE 129.TEVA PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 130.TEVA PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 131.TEVA PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 132.TEVA PHARMACEUTICALS: NET SALES,
TABLE 133.TEVA PHARMACEUTICALS: KEY STRATERGIES
TABLE 134.NOVARTIS: COMPANY SNAPSHOT
TABLE 135.NOVARTIS: OPERATING SEGMENTS
TABLE 136.NOVARTIS: PRODUCT PORTFOLIO
TABLE 137.NOVARTIS: NET SALES,
TABLE 138.NOVARTIS: KEY STRATERGIES
TABLE 139.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 140.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 141.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 142.GLAXOSMITHKLINE PLC: NET SALES,
TABLE 143.GLAXOSMITHKLINE PLC: KEY STRATERGIES
TABLE 144.BAYER AG: COMPANY SNAPSHOT
TABLE 145.BAYER AG: OPERATING SEGMENTS
TABLE 146.BAYER AG: PRODUCT PORTFOLIO
TABLE 147.BAYER AG: NET SALES,
TABLE 148.BAYER AG: KEY STRATERGIES
TABLE 149.SANOFI: COMPANY SNAPSHOT
TABLE 150.SANOFI: OPERATING SEGMENTS
TABLE 151.SANOFI: PRODUCT PORTFOLIO
TABLE 152.SANOFI: NET SALES,
TABLE 153.SANOFI: KEY STRATERGIES
TABLE 154.AMNEAL PHARMCEUTICALS LTD: COMPANY SNAPSHOT
TABLE 155.AMNEAL PHARMCEUTICALS LTD: OPERATING SEGMENTS
TABLE 156.AMNEAL PHARMCEUTICALS LTD: PRODUCT PORTFOLIO
TABLE 157.AMNEAL PHARMCEUTICALS LTD: NET SALES,
TABLE 158.AMNEAL PHARMCEUTICALS LTD: KEY STRATERGIES
TABLE 159.ASTRAZENCA PLC: COMPANY SNAPSHOT
TABLE 160.ASTRAZENCA PLC: OPERATING SEGMENTS
TABLE 161.ASTRAZENCA PLC: PRODUCT PORTFOLIO
TABLE 162.ASTRAZENCA PLC: NET SALES,
TABLE 163.ASTRAZENCA PLC: KEY STRATERGIES
TABLE 164.MYLAN N.V.: COMPANY SNAPSHOT
TABLE 165.MYLAN N.V.: OPERATING SEGMENTS
TABLE 166.MYLAN N.V.: PRODUCT PORTFOLIO
TABLE 167.MYLAN N.V.: NET SALES,
TABLE 168.MYLAN N.V.: KEY STRATERGIES
TABLE 169.AKIRA HEALTHCARE: COMPANY SNAPSHOT
TABLE 170.AKIRA HEALTHCARE: OPERATING SEGMENTS
TABLE 171.AKIRA HEALTHCARE: PRODUCT PORTFOLIO
TABLE 172.AKIRA HEALTHCARE: NET SALES,
TABLE 173.AKIRA HEALTHCARE: KEY STRATERGIES
TABLE 174.AURBINDO PHARMA: COMPANY SNAPSHOT
TABLE 175.AURBINDO PHARMA: OPERATING SEGMENTS
TABLE 176.AURBINDO PHARMA: PRODUCT PORTFOLIO
TABLE 177.AURBINDO PHARMA: NET SALES,
TABLE 178.AURBINDO PHARMA: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/

H&I Global Research

耳鼻咽喉科（ENT）疾患治療のグローバル市場（2020～2030）：抗生物質、抗炎症薬、その他

グローバル市場調査会社